[go: up one dir, main page]

GR3036064T3 - Tetrahydrolipstatin containing compositions - Google Patents

Tetrahydrolipstatin containing compositions

Info

Publication number
GR3036064T3
GR3036064T3 GR20010400907T GR20010400907T GR3036064T3 GR 3036064 T3 GR3036064 T3 GR 3036064T3 GR 20010400907 T GR20010400907 T GR 20010400907T GR 20010400907 T GR20010400907 T GR 20010400907T GR 3036064 T3 GR3036064 T3 GR 3036064T3
Authority
GR
Greece
Prior art keywords
tetrahydrolipstatin
containing compositions
compositions
tetrahydrolipstatin containing
Prior art date
Application number
GR20010400907T
Other languages
English (en)
Inventor
Navnit Shah
Max Zeller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26671373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3036064(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of GR3036064T3 publication Critical patent/GR3036064T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR20010400907T 1997-02-05 2001-06-18 Tetrahydrolipstatin containing compositions GR3036064T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3738497P 1997-02-05 1997-02-05
US09/003,137 US6004996A (en) 1997-02-05 1998-01-06 Tetrahydrolipstatin containing compositions
PCT/EP1998/000395 WO1998034607A1 (en) 1997-02-05 1998-01-24 Tetrahydrolipstatin containing compositions

Publications (1)

Publication Number Publication Date
GR3036064T3 true GR3036064T3 (en) 2001-09-28

Family

ID=26671373

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400907T GR3036064T3 (en) 1997-02-05 2001-06-18 Tetrahydrolipstatin containing compositions

Country Status (29)

Country Link
US (1) US6004996A (el)
EP (1) EP0921796B1 (el)
CN (1) CN1193752C (el)
AR (1) AR010704A1 (el)
AT (1) ATE200027T1 (el)
AU (1) AU713192B2 (el)
CA (1) CA2258095C (el)
CO (1) CO4920214A1 (el)
CY (1) CY2264B1 (el)
CZ (1) CZ287154B6 (el)
DE (1) DE69800639T2 (el)
DK (1) DK0921796T3 (el)
ES (1) ES2156028T3 (el)
GR (1) GR3036064T3 (el)
HR (1) HRP980057B1 (el)
HU (1) HU225035B1 (el)
ID (1) ID26509A (el)
IL (1) IL126902A (el)
MA (1) MA24466A1 (el)
MY (1) MY118371A (el)
NO (1) NO320445B1 (el)
NZ (1) NZ332659A (el)
PE (1) PE57599A1 (el)
PT (1) PT921796E (el)
RU (1) RU2170579C2 (el)
SI (1) SI0921796T1 (el)
UY (1) UY24875A1 (el)
WO (1) WO1998034607A1 (el)
YU (1) YU49423B (el)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901853T2 (xx) * 1997-02-05 1999-12-21 F. Hoffmann-La Roche Ag. Gastrointestinal lipaz inhibit�r�n�n kullan�lmas�.
PT1105122E (pt) * 1998-08-14 2005-08-31 Hoffmann La Roche Composicoes farmaceuticas que contem inibidores de lipase
WO2000013667A1 (en) * 1998-09-08 2000-03-16 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
MXPA02012583A (es) * 2000-06-27 2003-04-10 Hoffmann La Roche Metodo para preparacion de una composicion.
DE60110232T2 (de) * 2000-07-28 2006-01-19 F. Hoffmann-La Roche Ag Neue verwendung von lipase-inhibitoren
HRP20030029B1 (en) * 2000-07-28 2005-06-30 F. Hoffmann - La Roche Ag New pharmaceutical composition
PT1311260E (pt) 2000-08-09 2008-05-02 Hoffmann La Roche Utilização de inibidores de lipase para o tratamento da dispepsia
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2002221670B2 (en) 2000-10-16 2006-11-02 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-HT2 receptor ligands
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CA2432085C (en) 2000-12-27 2009-02-24 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
DE60225274T2 (de) 2001-05-21 2009-03-26 F. Hoffmann-La Roche Ag Chinolinderivate als liganden für den neuropeptid-y-rezeptor
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
EP1448169A1 (en) * 2001-11-07 2004-08-25 Fujisawa Pharmaceutical Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
EP1463488B1 (en) * 2001-12-20 2006-07-19 Alpex Pharma SA Pharmaceutical composition comprising skimmed milk powder
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
ES2304498T3 (es) * 2002-02-04 2008-10-16 F. Hoffmann-La Roche Ag Derivados de quinolina como antagonistas de npy.
DE60316411T2 (de) 2002-02-28 2008-06-12 F. Hoffmann-La Roche Ag Thiazolderivate als npy-rezeptorantagonisten
MXPA04010371A (es) * 2002-04-26 2005-02-03 Hoffmann La Roche Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan.
WO2004005265A1 (en) * 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Quinazoline derivatives
BR0313278A (pt) * 2002-08-07 2005-07-05 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos
ATE345340T1 (de) * 2002-09-12 2006-12-15 Hoffmann La Roche N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
AU2003292030B2 (en) * 2002-11-25 2007-01-04 F. Hoffmann-La Roche Ag Indolyl derivatives
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CA2533464A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
CN100422179C (zh) * 2003-08-12 2008-10-01 霍夫曼-拉罗奇有限公司 2-氨基-5-苯甲酰基噻唑npy拮抗剂
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CN101171252B (zh) * 2005-05-03 2011-06-01 霍夫曼-拉罗奇有限公司 作为5-ht2配体的四环氮杂吡嗪并二氢吲哚类化合物
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
ES2434072T3 (es) * 2005-06-09 2013-12-13 Norgine Bv Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona
EP1945635B1 (en) * 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
CN101316840B (zh) * 2005-11-30 2012-08-08 霍夫曼-拉罗奇有限公司 1,5-取代的吲哚-2-基酰胺衍生物
KR101047204B1 (ko) * 2005-11-30 2011-07-06 에프. 호프만-라 로슈 아게 Ｈ3 조절제로서 사용하기 위한1,1-다이옥소-싸이오모폴린일 인돌일 메탄온 유도체
ES2342979T3 (es) * 2005-11-30 2010-07-20 F. Hoffmann-La Roche Ag Derivados de indol-2-carboxamida sustituidos en 5.
DE602006010433D1 (de) * 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
CN101326187A (zh) * 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
US7351708B2 (en) * 2005-12-16 2008-04-01 Hoffmann-La Roche Inc. Pyrrolo [2,3-b] pyridine derivatives
EP1803714A1 (en) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
KR20080085031A (ko) * 2006-01-13 2008-09-22 에프. 호프만-라 로슈 아게 사이클로헥실 피페라지닐 메탄온 유도체 및 히스타민 ｈ3수용체 조절제로서의 이의 용도
AU2007206997B2 (en) * 2006-01-23 2011-11-24 F. Hoffmann-La Roche Ag Cyclohexyl sulfonamide derivatives having H3 receptor activity
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
BRPI0711740A2 (pt) * 2006-05-30 2011-12-06 Hoffmann La Roche compostos, processo para a sua manufatura,composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, método para o tratamento ou prevenção de obesidade, de diabetes do tipo ii, e uso dos compostos na manufatura de medicamentos
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
PL2002825T3 (pl) * 2007-06-14 2013-12-31 Krka Kompozycje farmaceutyczne zawierające orlistat
BRPI0817053A2 (pt) * 2007-09-17 2015-03-24 Reddys Lab Ltd Dr Formulações farmacêuticas de orlistat
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
MX2010004072A (es) * 2007-10-15 2010-09-14 Inventis Dds Pvt Ltd Composicion farmaceutica de orlistat.
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
MX342962B (es) 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
WO2012171561A1 (en) * 2011-06-15 2012-12-20 Synthon Bv Stabilized voriconazole composition
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
CN102362863B (zh) * 2011-11-21 2013-06-12 山东新时代药业有限公司 一种含奥利司他的制剂及其制备方法
WO2013092786A1 (en) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
AU2012101841A4 (en) * 2011-12-23 2013-01-17 Norgine Bv Compositions comprising cetilistat
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
EP2825183A4 (en) * 2012-03-13 2015-09-23 Piramal Entpr Ltd HERBAL COMPOSITION FOR THE TREATMENT OF METABOLISM DISEASES
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
EP2968333B1 (en) 2013-03-15 2022-01-12 NuSirt Sciences, Inc. Leucine and nicotinic acid for the reduction of lipid levels
CN104740637A (zh) * 2013-12-31 2015-07-01 北京科信必成医药科技发展有限公司 一种稳定的奥利司他口服制剂及其制备方法
SG11201607075TA (en) 2014-02-27 2016-09-29 Nusirt Sciences Inc Compositions and methods for the reduction or prevention of hepatic steatosis
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
CN108785272B (zh) * 2018-09-04 2019-04-09 中山万汉制药有限公司 一种奥利司他软胶囊及其制备方法
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
EP4422607A4 (en) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT
CN115300479A (zh) * 2022-08-23 2022-11-08 宁波高新区美诺华医药创新研究院有限公司 奥利司他胶囊制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor

Also Published As

Publication number Publication date
NO985337D0 (no) 1998-11-16
DE69800639T2 (de) 2001-10-31
NZ332659A (en) 2000-03-27
PT921796E (pt) 2001-09-28
DE69800639D1 (de) 2001-05-03
SI0921796T1 (en) 2001-06-30
CN1220600A (zh) 1999-06-23
PL330972A1 (en) 1999-06-21
YU49423B (sh) 2006-01-16
ES2156028T3 (es) 2001-06-01
HU0001468D0 (en) 2000-05-28
EP0921796A1 (en) 1999-06-16
US6004996A (en) 1999-12-21
CZ287154B6 (en) 2000-09-13
HUP0001468A3 (en) 2000-12-28
CO4920214A1 (es) 2000-05-29
MA24466A1 (fr) 1998-10-01
YU49698A (sh) 1999-09-27
MY118371A (en) 2004-10-30
IL126902A (en) 2002-12-01
AR010704A1 (es) 2000-06-28
AU713192B2 (en) 1999-11-25
HUP0001468A2 (hu) 2000-09-28
DK0921796T3 (da) 2001-07-16
HK1021313A1 (en) 2000-06-09
WO1998034607A1 (en) 1998-08-13
HU225035B1 (en) 2006-05-29
PE57599A1 (es) 1999-06-11
AU6097298A (en) 1998-08-26
CN1193752C (zh) 2005-03-23
RU2170579C2 (ru) 2001-07-20
CA2258095A1 (en) 1998-08-13
ID26509A (id) 2001-01-11
HRP980057A2 (en) 1998-12-31
NO985337L (no) 1998-11-16
NO320445B1 (no) 2005-12-05
EP0921796B1 (en) 2001-03-28
HRP980057B1 (en) 2001-08-31
IL126902A0 (en) 1999-09-22
ATE200027T1 (de) 2001-04-15
CZ352898A3 (cs) 1999-02-17
CY2264B1 (en) 2003-07-04
UY24875A1 (es) 2000-12-29
CA2258095C (en) 2000-02-22

Similar Documents

Publication Publication Date Title
CY2264B1 (en) Tetrahydrolipstatin containing compositions
HUP9903759A3 (en) Abtimicrobial compositions
GB9508691D0 (en) Stable compositions
GB9726814D0 (en) Compositions
GB9702238D0 (en) Compositions
PL334568A1 (en) Paroxetin containing compositions
PL327833A1 (en) Diosegnin containing compositions
GB9726543D0 (en) Novel compositions
GB9724838D0 (en) Compositions
GB9701031D0 (en) Composition
GB9705340D0 (en) Compositions
GB9703109D0 (en) Compositions
ZA98746B (en) Tetrahydrolipstatin containing compositions
GB9705813D0 (en) Novel compositions
GB9712981D0 (en) Compositions
GB2336368B (en) Compositions
EG23068A (en) Pesticidale composition
GB9703611D0 (en) Compositions
GB9713215D0 (en) Compositions
GB9708791D0 (en) Compositions
GB9705413D0 (en) Compositions
GB9709127D0 (en) Compositions
GB9704799D0 (en) Compositions
GB9704427D0 (en) Compositions
GB9703375D0 (en) Compositions